FTC orders Illumina to divest $7.1 billion acquisition of cancer test developer Grail

The decision reverses an administrative judge's ruling that dismissed the FTC's initial challenge of Illumina's $7.1 billion Grail deal.

from Health and Science https://ift.tt/Lyaf5Yn
https://ift.tt/8P6NpFS
https://ift.tt/DHE4vS2